Huge congrats to Cathy Handy Marshall, MD MPH and Benjamin Teply for this paradigm-breaking study. In BCR prostate cancer, Olaparib shows profound activity (w/out ADT!) in HRRm+ pts, esp. in BRCA2+ pts (100% response rate). The PCCTC Johns Hopkins Kimmel Cancer Center @umncancer jamanetwork.com/journals/jamao…

Prognostic power of multi-modal #ArtificialIntelligence biomarker in #CHAARTED trial subset. Mark C. Markowski and Zach Klaassen discuss advancements in AI, particularly the ArteraAI Prostate Test, and its implications for #ProstateCancer treatment > bit.ly/3WrT3tH

Olaparib produced responses in high-risk, biochemically recurrent prostate cancer with HRR alterations, particularly BRCA2 alterations. JAMA Oncology #pcsm #oncology onclive.com/view/olaparib-…

The Vanderbilt University Ingram Cancer Center Genitourinary team is expanding. We are seeking a GU medical oncology clinical investigator to join our innovative team. Please message me or Brian Rini, MD to inquire further. We will also be at #ESMO24

Such an incredibly important ‘negative’ study. Well designed and executed. Excellent job, Toni Choueiri, MD and team

Super excited to see this work from Sangeeta Ray and her group! pubmed.ncbi.nlm.nih.gov/39324008/ nirm @cpavmd Michael Gorin, M.D. Mark C. Markowski liljasol. #PSMA #molecularimaging #theranostics

Our haiku about #prostatecancer and the #PCFRetreat24 with Prostate Cancer Foundation by Pedro F. S. Freitas, MD Sylvan Baca MD PhD (Hiring!) What do you think? 😊 Rana McKay, MD, FASCO Emmanuel Antonarakis Mark C. Markowski Toni Choueiri, MD Howard Soule Andrea Miyahira Misha Beltran Josh Lang

The Vanderbilt GU Program is looking for new faculty members. Clinical investigators with an interest in translational investigator-initiated trials across GU malignancies are preferred. Message me /Alan Tan for more details! Come work with stellar faculty in an amazing city!

Just opened a new GU Med Onc position Fred Hutch Cancer Center UW Medicine join our dynamic cohesive team committed to exceptional care, innovative research, mentorship, teaching, DEI, community outreach! apply.interfolio.com/158802 Nicole D. Fleming MD Jessica Hawley MD MS Hsieh Lab Dr. Tom Lynch

Great exchange of ideas and hope to collaborate in the future!@AarmstrongDuke , Mark C. Markowski . Thanks to our Colleagues for your expertise Program for the Multidisciplinary Management of Prostate Cancer held at the National Cancer Institute Instituto Nacional de Cancerología

Your natural history study with PSMA PET imaging will be incredibly important. We did not find an association between PSADT and a positive PSMA PET. To me this suggests that novel imaging may not inform who needs treatment. PSADT still the gold standard.

Bigger kid. Bigger fish. Happy Thanksgiving 2024!

Ravi A Madan M.D. Johns Hopkins Medicine Emmanuel Antonarakis David Einstein Russell Pachynski Fatima Karzai, M.D. Edwin Posadas, MD Cathy Handy Marshall, MD MPH Laura Sena Mark C. Markowski Marijo Bilusic, MD, PhD Channing Paller We would like to inform you that your post has been published on OncoDaily. Thank you for sharing! oncodaily.com/blog/193154

Such a pleasure working with ECOG-ACRIN Cancer Research Group and Christopher Sweeney, MBBS. Multimodal AI prostate test by ArteraAI prognostic for OS in patients with mHSPC on CHAARTED trial. Hopeful AI will predict response to treatment as next step. sciencedirect.com/science/articl…

Congrats to Etan Aber from NCI CCR GU Malignancies who lead this effort. Preliminary but provocative retrospective data showing PSA responses with SGLT2 inhibitors in patients with prostate cancer in absence of ADT. onlinelibrary.wiley.com/doi/10.1002/pr…

See you in 2025. Happy New Year!

Can’t wait to talk about prostate cancer with patients and their caregivers.

Cancer Statistics 2025 are out! #prostatecancer incidence still on the rise, mortality basically flat. Get screened so you can get treatment _when needed_. #pcsm acsjournals.onlinelibrary.wiley.com/doi/epdf/10.33…

Phase 2 trial of single agent rucaparib without ADT in patients with mHSPC who harbor germline mutations in HRR genes. Clinical and objective responses observed. Mark C. Markowski doi.org/10.1093/oncolo…

Very cool - nice work.